Posted by Michael Wonder on 30 Mar 2017
pERC publishes final recommendation for Sanofi Genzyme's Caprelsa
30 March 2017 - The recommendation relates to the use of vandetanib for the treatment of symptomatic and/or progressive medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease.
The pERC has recommended the reimbursement of vandetanib on the condition that its cost-effectiveness being improved to an acceptable level.
Funding is recommended for those with a good performance status and treatment should be discontinued upon disease progression or unacceptable toxicity.
